What's in Astellas Pharma Inc.'s pipeline?

Astellas Pharma Inc. has 20 drugs in our index: 20 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Astellas Pharma Inc.'s portfolio?

Top competitors by shared drug class: , Sun Pharma, Pfizer Inc., AbbVie, Aragon Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/astellas.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Astellas Pharma Inc. — Portfolio Competitive Intelligence Brief

Astellas Pharma Inc. (ALPMY) pipeline: 20 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ALPMY (OTC) 20 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Vyloy	ZOLBETUXIMAB	marketed	Claudin 18.2-directed Cytolytic Antibody [EPC]		Oncology	2024-01-01
Veozah	FEZOLINETANT	marketed	Neurokinin 3 Receptor Antagonist [EPC]	Neuromedin-K receptor	Neuroscience	2023-01-01
Izervay	AVACINCAPTAD PEGOL	marketed		Complement C5	Immunology	2023-01-01
Evrenzo	ROXADUSTAT	marketed		Thyroid hormone receptor beta	Hematology	2021-01-01
Padcev Ejfv	enfortumab-vedotin	marketed		Nectin-4	Oncology	2019-01-01
Padcev	AGS-22M6E	marketed		Nectin-4	Oncology	2019-01-01
Enfortumab	padcev	marketed		Nectin-4	Oncology	2019-01-01
Xospata	GILTERITINIB	marketed		Leukocyte tyrosine kinase receptor	Oncology	2018-01-01
Cresemba	ISAVUCONAZONIUM	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	Infectious Disease	2015-01-01
Xtandi	xtandi	marketed	Androgen receptor inhibitor	Androgen receptor	Oncology	2012-01-01
Xtandi	enzalutamide	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	Oncology	2012-01-01
Vesicare	SOLIFENACIN	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	Urology	2004-01-01

Therapeutic area mix

Oncology · 8
Immunology · 4
Neuroscience · 2
Other · 2
Urology · 1
Hematology · 1
Infectious Disease · 1
Bone · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-05-15 — Xtandi · 9126941 · US
2026-08-24 — Xtandi · 8183274 · US
2027-08-13 — Xtandi · 7709517 · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-08-30 — Prograf · 8664239 · Method of Use · US
2028-08-30 — Prograf · 8685998 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 5 shared drug classes
Sun Pharma · 2 shared drug classes
Pfizer Inc. · 2 shared drug classes
AbbVie · 1 shared drug class
Aragon Pharmaceuticals, Inc. · 1 shared drug class
Arvinas Androgen Receptor, Inc. · 1 shared drug class
Aqua Pharms · 1 shared drug class
AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Astellas Pharma Inc.:

Cite this brief

Drug Landscape (2026). Astellas Pharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astellas. Accessed 2026-05-13.